RE: Can anyone answer the following question? Well Plovie...Proud owner of 5,000 shares.
I would suggest that if Endo fails on P3B the entire C level of our partner is walking the plank, with the full board following closely behind.
A 2 bil market cap company does not embark on the largest trial in their existence, with an encyclopedia of supporting data in hand, a P3a trial with excellent results in their pocket, a fast track/SPA protocol, burn nearly 4 mil a month, add sites and patients continuously on an international scale, all amidst a global shortage of its less than stellar competition and allow any survivors should it fail.
Of course being a wall street MBA as you are, that should be a given shouldn't it.